Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
VANCOUVER, British Columbia, Aug. 14, 2015 (GLOBE NEWSWIRE) -- MPH Ventures Corp. (TSX-V:MPS) (OTCBB:MPSFF) (Frankfurt:IJA2) (the "Company") announces, further to its news release of July 08th, that...
-
Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched...
-
Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched in four European...
-
Antimykotikum CRESEMBA® (Isavuconazol) erhält US-Zulassung sowie Zulassungsempfehlung für die Europäische Union Antibiotikum Zevtera®/Mabelio® (Ceftobiprol Medocaril) derzeit in vier...
-
Basel, 12. August 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) Ceftobiprol den Status eines...
-
Basel, Switzerland, August 12, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a...
-
Basel, 30. Juli 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute die Topline-Ergebnisse der Phase-3-Studie ACTIVE bekannt. Die randomisierte, doppelt verblindete Studie untersuchte die...
-
Basel, Switzerland, July 30, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today topline results from the phase 3 ACTIVE study. The randomized double-blind study evaluated the efficacy and...
-
BASEL, Switzerland, July 24, 2015 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
-
Basel, Switzerland, July 24, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a...